Disclaimer: Consult with a doctor before deciding on a treatment plan for cancer or any other disease
Salinomycin is a powerful cancer treatment. It is an antibiotic that’s been used to treat infections in poultry, but despite its demonstrated ability to cure human diseases like cancer and malaria, it is rarely used in humans because it would negate the need for conventional treatments like chemotherapy, radiation, and surgery. Sigma owns the patent rights to salinomycin which is why this drug is so hard to find despite its ability to cure major diseases.
Salinomycin (also known in some circles as “Sal”) is a polyether ionophore antibiotic that has been isolated from Streptomyces albus. Research has shown that it has the ability to kill Cancer Stem Cells (CSC’s) in a variety of different human cancers .
Salinomycin was developed in the 1960’s and has been in use since for over 3 decades as an agricultural antibiotic that’s used to prevent coccidiosis in poultry. It also improves nutrient absorption in other ruminant animals and swine. As an ionophore, salinomycin can transport specific ions across cellular membranes in both directions to promote cellular healing or apoptosis. Salinomycin shows a particular affinity for potassium and a preference for alkali ions in general .
The alkali ions include:
- Lithium – Li
- Sodium – Na
- Potassium – K
- Rubidium – Rb
- Cesium – Cs
- Francium – Fr
Note that an entire therapeutic cancer protocol has been developed around the use of Cesium to increase the pH in the body. High enough levels of Cesium causes cancer cells to die within 2 to 3 days. Pain caused by cancer is relieved within 12 hours .
Salinomycin interferes with the normal movement of potassium across the cellular membrane causing potassium ions (K+) from the mitochondria and cytoplasm of the cell to leave the cell .
CSC’s have the ability to resist chemotherapy, radiation, and tumor-targeted drugs. They also have the ability to self-renew and initiate the development of new tumors in new areas of the body. Doctors who ascribe to the cancer stem cell model of carcinogensis seek to eradicate all cancer stem cells in the body .
Breast cancer growth and metastasis in mice has been successfully curbed through the use of salinomycin . And in research settings, salinomycin has been able to kill a variety of human cancer cells with drug and apoptosis resistance. This drug has been intensively studied for its effectiveness against various cancers . By activating unconventional pathways that lead to cellular death, salinomycin has been able to combat cancer cell resistance to apoptosis. Salinomycin targets both CSC’s and apoptosis-resistant cancer cells .
Research has shown that salinomycin can kill cancer stem cells in the following types of cancer. It may also be effective against other types of cancer not listed below:
- Lung cancer 
- Breast cancer 
- Leukemia 
- Colorectal Cancer 
- Colon Carcinoma 
- Ovarian cancer 
- Prostate Cancer 
- Pancreatic Cancer 
- Epithelial Cancers (“carcinomas”) – breast, ovarian, lung, thyroid, adrenal, pituitary, etc. 
Salinomycin has been widely researched for its effectiveness against CSC’s in a variety of different types of cancers in part because doctors and scientists combine this treatment with other “conventional” chemotherapy agents . In this context, as an adjunct therapy, salinomycin is not as big of a threat to pharmaceutical companies.
Salinomycin is a patented pharmaceutical which has made it more “fundable” in mainstream medicine. When a substance does not occur in nature, it can be patented and when a substance can be patented, it can be branded and marketed by pharmaceutical companies. Therefore, salinomycin was a profitable idea, at least up to a point. But curing patients is not as profitable as keeping them just a little sick according to analysts at Goldman Sachs . So, shortly after the discovery of its anti-cancer properties, salinomycin was patented by scientists at Verastem under the name VS-507 . As Verastem geared up to go through the Phase I FDA trials, (they planned to focus on “triple negative” breast cancer dealing with patients who have no other conventional cancer treatment options left), news stories appeared to squelch the research. Below is a media quote about Verastem in 2012 from “The Street”:
“As I said above, Verastem won’t start dosing humans with VS-507 until next year. The company’s biological hypothesis itself—I will spare you the details—has no clinical validation whatsoever and the company’s development program lags at least eight CSC-focused competitors including Novartis, Roche, Pfizer, and privately held OncoMed Pharmaceuticals. Many of these competitors already have clinical data in hand. As a decades-old drug, salinomycin has no composition-of-matter patent; Verastem intends to file for less compelling formulation and method-of-use patents, but has not yet done so .
Though multiple studies have examined the mechanism of action by which salinomycin is able to target CSC’s , the article quoted above, which ranked at the top of the page on a Google search categorically dismissed the research as pure quackery with one sentence. Such is the state of Internet-based information about important cancer treatments like salinomycin.
In addition to its potential as an effective anti-cancer drug salinomycin has also been shown as a potential drug that could cure malaria and prevent its transmission to new carriers . Since malaria is one of the other biggest money-makers for pharmaceutical industry (approximately half of the world’s population is at risk for developing malaria) , salinomycin never stood a chance at being approved by the FDA and moving into mainstream, conventional medicine for the treatment of this disease.
The political spin on salinomycin has not completely removed it from mainstream medicine and research, but it has considerably diminished its importance and its presence. Salinomycin quickly kills malaria, compared to standard drug therapies currently on the market and it does so without hurting normal, healthy red blood cells . As such, this drug, though patentable and therefore profitable, would hurt pharmaceutical companies because it would ultimately lead patients to a cure for two very profitable world-wide diseases: cancer and malaria. And Goldman-Sachs has analysts who have decreed that cures are not profitable .
Today, salinomycin is quietly marketed by Sigma-Aldrich. It’s data sheets make sure to mention how conventional chemotherapy agents “kill the bulk tumor cells” and salinomycin can kill CSC’s in breast and lung tissue (without mention of salinomycin’s success as a sole treatment of cancer –not just the CSC’s- or other cancer types that have been studied). The Sigma-Aldrich Product Information sheet also fails to mention that the number of patients who survive past 5 years after doing chemotherapy treatment is only 2.3% in Australia and 2.1% in the United States . Clearly, based on the statistics chemotherapy is only rarely successful at killing the bulk of tumor cells.
Safety and Effectiveness
Studies have demonstrated that salinomycin strongly inhibits the proliferation of cancer cells, including multi-drug resistant cancer cells as well as CSC’s. Clinical studies have shown tumor regression with only transient side effects that disappear shortly after the application of salinomycin . Carboxylic ionophores such as salinomycin have been found to be safe and effective when patients are given the correct dose .
How Salinomycin Is Administered
Salinomycin is administered intravenously, orally, or via injection.
Rats were treated for malaria with a single oral dose of salinomycin at 80 mg/kg. Within one hour, the malaria parasites were in a state of degeneration. Within 22 hours, malaria parasites had disappeared completely from blood smears.
Possible Negative Effects
It is possible to overdose on salinomycin or experience and drug-drug interaction. Symptoms of overdose include:
- Lack of appetite
- Shortness of breath
- Loss of some/all control of body movement
Other Important Information
Salinomycin treatment is offered in Tijuana, Mexico at the following facility:
Immunity Therapy Center
Also, Dr. Rosenberg treats cancer patients, particularly chemo-resistant patients in Central and South America with salinomycin. For more information about about salinomycin treatment contact Angie Holder at [email protected] or (251)-943-9409.
 Naujokat, C. & Steinhart, R. (2012). Salinomycin as a Drug for Targeting Human Cancer Stem Cells. Retrieved April 19, 2018 from https://www.hindawi.com/journals/bmri/2012/950658/
 Naujokat, C., Fuchs, D., Opelz, G. (2010). Salinomycin in cancer: A new mission for an old agent. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/21472278/
 Brewer, A. K. (1984). The High pH Therapy for Cancer Tests on Mice and Humans. Retrieved March 14, 2018 from https://20975-presscdn-pagely.netdna-ssl.com/wp-content/uploads/2014/02/The-high-pH-therapy-for-cancer-tests-on-mice-and-humans.pdf
 Huczynski, A. (2012). Salinomycin: a new cancer drug candidate. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/22145602
 Wang, Y. (2011). Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Retrieved April 19, 2017 from https://www.ncbi.nlm.nih.gov/pubmed/21222617
 Zhou, J., Li, P., Xue, X., et al. (2013). Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species. Retrieved April 19, 2017 from https://www.ncbi.nlm.nih.gov/pubmed/23916687
 Parajuli, B., Shin, S. J., Kwon, S. H., et al. (2013). Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/23564786
 Antoszczak, M., Huczynski, A. (2015). Anticancer Activity of Polyether Ionophore-Salinomycin. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/25553435
 Dewangan, J., Srivastava, S., Rath, S. K. (2017). Salinomycin: A new paradigm in cancer therapy. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/28349817
 Mihaela Catalina Stanciu Foundation for Life (2015). Salinomycin: One of the Best. Retrieved April 19, 2018 from https://www.cancertreatmentsresearch.com/salinomycin/
 Mole, B. (2018). Is curing patients a sustainable business model? Goldman Sachs analysts ask. Retrieved April 19, 2018 from https://arstechnica.com/tech-policy/2018/04/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say/
 Sadeghi-Nejad, N. (2012). Verastem and the Broken Wall Street Research Model. Retrieved April 19, 2018 from https://www.thestreet.com/story/11451571/1/verastem-and-the-broken-wall-st-research-model.html
 Klose, J., Eissele, J., Volz, C., et. Al (2016). Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133+ human colorectal cancer cells. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/27855654
 He, L., Wang, F., Dai, W. Q., et. al (2013). Mechanism of action of salinomycin on growth and migration in pancreatic cancer cell lines. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/23395573
 Elsevier, B. V. (2018). Salinomycin. Retrieved April 19, 2018 from https://www.sciencedirect.com/topics/neuroscience/salinomycin
 PubChem (n.d.). Salinomycin: Drug and Medication Information. Retrieved April 19, 2018 from https://pubchem.ncbi.nlm.nih.gov/compound/salinomycin#section=Drug-and-Medication-Information
 D’Alessandro, S., Corbett, Y., Ilboudo, D., et. al. (2015). Salinomycin and other ionophores as new class of antimalarial drugs with transmission blocking activity. Retrieved April 19, 2018 from http://aac.asm.org/content/early/2015/06/03/AAC.04332-14.abstract
 World Health Organization. (2016). 10 facts on malaria. Retrieved April 19, 2018 from http://www.who.int/features/factfiles/malaria/en/
 Melhorn, H., Ganster, H. J., & Raether, W. (1984). Effect of salinomycin-Na on malaria parasites (Plasmodium falciparum and P. berghei). Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/6375210
 Sigma-Aldrich Co. LLC. (2012). Product Information: Salinomycin from Streptomyces albus. Retrieved April 19, 2018 from https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/1/s4526pis.pdf
 Chris Beat Cancer (2018). Study: Chemo Is Only 2.1% Effective Toward 5 Year Survival [8 Min.]: How effective is chemotherapy, really? Retrieved April 21, 2019 from https://www.chrisbeatcancer.com/how-effective-is-chemotherapy/
 Morgan, G., Ward, R., Barton, M. (2004). The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Retrieved April 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/15630849